You are here » Home » Companies » Company Overview » Dr Agarwals Eye Hospital Ltd

Dr Agarwals Eye Hospital Ltd.

BSE: 526783 Sector: Health care
NSE: N.A. ISIN Code: INE934C01018
BSE 00:00 | 23 Jun 414.60 0
(0.00%)
OPEN

400.15

HIGH

420.00

LOW

400.15

NSE 05:30 | 01 Jan Dr Agarwals Eye Hospital Ltd
OPEN 400.15
PREVIOUS CLOSE 414.60
VOLUME 704
52-Week high 446.00
52-Week low 213.00
P/E
Mkt Cap.(Rs cr) 195
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 400.15
CLOSE 414.60
VOLUME 704
52-Week high 446.00
52-Week low 213.00
P/E
Mkt Cap.(Rs cr) 195
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Dr Agarwals Eye Hospital Ltd. (DRAGARWALSEYE) - Chairman Speech

Company chairman speech

Dear Shareholders

Hope you and your family are well and safe in these testing times. The world is facingan unprecedented scenario and we at Dr. Agarwals commend the effort of the front-linewarriors who have gone above and beyond their call of duty to keep us all safe.

We started our journey 63 years ago with a challenge to build an organization thatwould offer high quality eye care at affordable prices. This continued effort over theyears has helped us earn the trust of millions of people across the world while stayingtrue to our vision of being a truly global healthcare organization which imbibes the bestpractices in the sector while relying on continuous innovation and cutting–edgetechnology.

For FY 2019-20 we clocked INR 178.60 Crores as the total income and our EBITDA stoodat 27.36%. Due to the COVID-19 crisis the momentum in our peak month of March gotderailed and for nearly 15 days in March our revenues dropped down drastically. Our Q121 performance has been affected due to the cascading impact of COVID-19 crisis andnationwide lockdown in India. However we believe that the COVID-19 crisis is a temporarysetback and we will bounce back by showing a better run rate Q2 21 onwards. To rejuvenatethe organization from this pandemic our mantra for the FY 2020-21 will be to focus oncost efficiency operational optimization and optimal growth rate. We would be relocatingour Salem branch (by Q3 21) to a bigger premise to address the market demands and weexpect to gain more market share with this move. We have also strengthened our complianceprocess and will continue to do so.

As we move ahead on the path of value creation for all our stakeholders I would liketo commend the effort of our Doctors Consultants management and staff. I thank all thedirectors for their valued insights and directions imparted to the Company. The trust andconfidence of the shareholders fuel us on the path of excellence and I look forward tothis continued support.